BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

NCT02805023 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Limb-Threatening Ischemia
Peripheral Arterial Disease
Peripheral Vascular Disease

Interventions

BIOLOGICAL: BGC101 (autologous EnEPC preparation)
BIOLOGICAL: Control medium

Sponsor

BioGenCell Ltd.

Collaborators

[object Object]
[object Object]